HERVolution Therapeutics Demonstrates Preclinical Proof-of-Concept for Insulin Sensitization Immune Therapy in Metabolic Disease and Announces Exclusive License Agreement with the University of Copenhagen

HERVolution Therapeutics Demonstrates Preclinical Proof-of-Concept for Insulin Sensitization Immune Therapy in Metabolic Disease and Announces Exclusive License Agreement with the University of Copenhagen

PR Newswire

COPENHAGEN, Denmark and NEW YORK, June 10, 2026

Preclinical studies in disease-relevant models demonstrate the ability of HERVolution's HERV-targeting platform to control weight gain, reverse type 2 diabetes, and lower "inflammaging" biomarkersExclusive license agreement, combined with core company-owned IP, further solidifies the potential of IPT-001 in metabolic disease and longevityCOPENHAGEN, Denmark and NEW YORK, June 10, 2026 /PRNewswire/ -- HERVolution Therapeutics ApS, a biotechnology company pioneering human endogenous retrovirus (HERV)-targeting immunotherapies for metabolic diseases, longevity, and oncology, today announced preclinical proof-of-concept for its proprietary technology in metabolic disease, presented at the American Diabetes Association 2026 Scientific Sessions, held June 5-8, 2026, in New Orleans. The company concurrently announced an exclusive license agreement with the University of Copenhagen (UCPH) covering the commercialization of HERV-targeting technology for controlling weight gain.